Bispecific Antibodies Market to Reach USD 39.9 Billion by 2032

Treatment-line expansion is becoming more important than new molecule count as bispecific therapies move into first relapse, second-line disease and larger solid-tumor populations

The Global Bispecific Antibodies Market was valued at approximately USD 16.6 billion in 2025 and is projected to reach USD 39.9 billion by 2032, expanding at a CAGR of approximately 13.3% during 2026–2032.

The strongest commercial change in the market is the movement of bispecific therapies into earlier stages of treatment, where substantially more patients remain clinically eligible.

This is particularly important in multiple myeloma and lymphoma, where late-line treatment historically restricted bispecific use to patients who had already progressed through several therapies. Earlier positioning increases the reachable patient pool before disease progression, cumulative toxicity, declining performance status or competing therapies remove patients from consideration.

Earlier-Line Access Is Increasing the Number of Treatable Patients

Multiple myeloma provides the clearest example.

BCMA- and GPRC5D-directed bispecific antibodies initially entered heavily pretreated disease, but treatment is increasingly moving toward earlier relapse. This changes the revenue opportunity because the commercially relevant population after one prior line is materially larger than the population remaining after four or more previous therapies.

The market is therefore shifting from a late-line rescue model toward a sequencing model, where manufacturers compete for position across repeated relapse rather than for a single narrow treatment window.

The same pattern is emerging in DLBCL and follicular lymphoma as CD20-directed bispecific therapies move closer to second-line and first-relapse treatment.

Solid Tumors Are Becoming the Largest Source of New Addressable Patients

Small-cell lung cancer has provided an important commercial proof point for bispecific T-cell engagement outside hematologic malignancies.

Imdelltra generated USD 627 million in 2025 sales, demonstrating that a bispecific therapy can achieve meaningful uptake in a solid tumor within a relatively short commercial period.

The strategic importance extends beyond SCLC.

Late-stage development in prostate, gastric and other solid tumors means future market expansion could come from entirely new patient populations, rather than additional products competing for the same hematology patients.

Programs targeting STEAP1, CLDN18.2 and other solid-tumor antigens are therefore important because successful development could materially increase the addressable market ceiling.

Biomarker Identification Is Becoming a Direct Revenue Constraint

As the market expands into precision solid-tumor treatment, patient identification is becoming commercially critical.

Theoretical eligibility does not translate automatically into treated patients. Revenue depends on whether the relevant biomarker is tested, identified and acted on before disease progression changes the treatment decision.

This means molecular testing, protein-expression assays and pathology workflows are becoming part of the market's commercial infrastructure.

For precision bispecifics, testing penetration can directly determine treatment penetration.

The U.S. Market Remains the Main Revenue Concentration

The United States Bispecific Antibody Market was approximately USD 9.7 billion in 2025, representing about 58% of global revenue.

Its high contribution reflects strong uptake of high-value biologics, specialist treatment infrastructure and relatively broad access to molecular testing.

The U.S. is also becoming the key market for evaluating whether bispecifics can scale outside narrowly defined late-line populations.

Future revenue growth will increasingly depend on adoption in earlier multiple myeloma, lymphoma and solid-tumor treatment settings rather than continued reliance on heavily pretreated patients.

Treatment Sequencing Is Becoming the Main Competitive Battleground

Competitive differentiation is also changing.

The market is no longer defined primarily by whether a company has a bispecific molecule in development.

Commercial positioning increasingly depends on:

• how early the therapy can be used,
• whether it preserves treatment options for later relapse,
• how it fits against CAR-T and other targeted therapies,
• whether toxicity allows broader treatment-center use,
• and whether patients can remain on therapy long enough to generate durable clinical and commercial value.

In multiple myeloma, the coexistence of BCMA, GPRC5D and emerging alternative targets is making sequencing increasingly important.

In lymphoma, bispecifics must compete with CAR-T and established salvage approaches.

In solid tumors, the key challenge is whether target selectivity can support sufficient efficacy without creating toxicity that limits routine use.

The USD 39.9 Billion Forecast Depends on Broader Treatment Access, Not Pipeline Volume Alone

The projected increase from USD 16.6 billion in 2025 to USD 39.9 billion by 2032 is therefore not based simply on more bispecific drugs entering development.

The larger revenue opportunity comes from three structural shifts:

late-line therapy moving earlier, hematology expanding into treatment sequences, and bispecific platforms entering large solid-tumor populations.

Established franchises in hemophilia and ophthalmology provide the current revenue base, while oncology is expected to contribute a greater share of incremental growth as therapies reach patients earlier and enter new diseases.

The commercial direction of the market is becoming clear: revenue growth will increasingly follow patient access, treatment position and disease expansion rather than molecule count alone.